HRP20030575B1 - Preparation of non-crystalline atorvastatin calcium - Google Patents
Preparation of non-crystalline atorvastatin calciumInfo
- Publication number
- HRP20030575B1 HRP20030575B1 HR20030575A HRP20030575A HRP20030575B1 HR P20030575 B1 HRP20030575 B1 HR P20030575B1 HR 20030575 A HR20030575 A HR 20030575A HR P20030575 A HRP20030575 A HR P20030575A HR P20030575 B1 HRP20030575 B1 HR P20030575B1
- Authority
- HR
- Croatia
- Prior art keywords
- atorvastatin
- protecting group
- water
- group
- solution
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 2
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
- 229960005370 atorvastatin Drugs 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical compound OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200100010A SI20814A (sl) | 2001-01-23 | 2001-01-23 | Priprava amorfnega atorvastatina |
PCT/IB2002/000161 WO2002059087A1 (en) | 2001-01-23 | 2002-01-22 | Preparation of non-crystalline atorvastatin calcium |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20030575A2 HRP20030575A2 (en) | 2005-06-30 |
HRP20030575B1 true HRP20030575B1 (en) | 2011-10-31 |
Family
ID=20432812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030575A HRP20030575B1 (en) | 2001-01-23 | 2003-07-15 | Preparation of non-crystalline atorvastatin calcium |
Country Status (27)
Country | Link |
---|---|
US (2) | US6750353B2 (ko) |
EP (1) | EP1373202B1 (ko) |
JP (1) | JP4336106B2 (ko) |
KR (1) | KR100882066B1 (ko) |
CN (1) | CN1260213C (ko) |
AT (1) | ATE294159T1 (ko) |
AU (1) | AU2002219455B2 (ko) |
BG (1) | BG108017A (ko) |
BR (1) | BR0206637A (ko) |
CA (1) | CA2435954C (ko) |
CZ (1) | CZ20031988A3 (ko) |
DE (1) | DE60203894T2 (ko) |
DK (1) | DK1373202T3 (ko) |
EE (1) | EE05270B1 (ko) |
ES (1) | ES2240748T3 (ko) |
HR (1) | HRP20030575B1 (ko) |
HU (1) | HU227535B1 (ko) |
IL (2) | IL157068A0 (ko) |
MX (1) | MXPA03006548A (ko) |
PL (1) | PL209428B1 (ko) |
RS (1) | RS51010B (ko) |
RU (1) | RU2324679C2 (ko) |
SI (2) | SI20814A (ko) |
SK (1) | SK286593B6 (ko) |
UA (1) | UA73829C2 (ko) |
WO (1) | WO2002059087A1 (ko) |
ZA (1) | ZA200305307B (ko) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2622477A1 (en) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
WO2002068335A2 (en) * | 2001-02-27 | 2002-09-06 | Council Of Scientific And Industrial Research | Essential oil composition for potable water disinfection |
PL367943A1 (en) | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
HU227124B1 (en) * | 2001-09-14 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin |
KR20090045420A (ko) | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
EP1615884B1 (en) * | 2003-04-11 | 2016-06-29 | LEK Pharmaceuticals d.d. | Process for the preparation of amorphous calcium salt of atorvastatin |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
SK50112006A3 (sk) | 2003-07-02 | 2006-05-04 | Egis Gy�Gyszergy�R Rt. | Spôsob prípravy amorfnej formy liečiva - inhibítora zrážania krvných doštičiek |
AU2003247327A1 (en) * | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
AU2003272082A1 (en) * | 2003-10-07 | 2005-04-21 | Biocon Limited | Process for the production of atorvastatin calcium |
EP1711489B1 (en) * | 2003-12-29 | 2012-12-26 | LEK Pharmaceuticals d.d. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
CN1942439B (zh) | 2004-03-17 | 2011-12-21 | 兰贝克赛实验室有限公司 | 无定形形式的阿托伐他汀钙的制备方法 |
JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
WO2006008091A2 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
EP1771412A2 (en) * | 2004-07-20 | 2007-04-11 | Warner-Lambert Company LLC | Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1) |
WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
EP1784389A4 (en) * | 2004-08-27 | 2009-03-25 | Biocon Ltd | PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM |
EP1807055A1 (en) | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
EP1979313A1 (en) * | 2006-01-31 | 2008-10-15 | Jubilant Organosys Limited | Process for the preparation of amorphous atorvastatin calcium salt |
CN100406438C (zh) * | 2006-06-30 | 2008-07-30 | 浙江新东港药业股份有限公司 | 一种无定型阿伐他汀钙的制备方法 |
US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
BRPI0818575A2 (pt) * | 2007-10-17 | 2014-10-07 | Todd F Ovokaitys | Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo |
WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium |
KR101050722B1 (ko) | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
WO2011131605A1 (en) * | 2010-04-19 | 2011-10-27 | Dsm Ip Assets B.V. | Production of atorvastatin low in ether impurities |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
US10202598B2 (en) | 2014-05-30 | 2019-02-12 | Todd Frank Ovokaitys | Methods and systems for generation, use, and delivery of activated stem cells |
US10384985B2 (en) | 2014-06-06 | 2019-08-20 | B.K. Consultants, Inc. | Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants |
WO2015187974A1 (en) | 2014-06-06 | 2015-12-10 | Ovokaitys Todd Frank | Methods and compositions for increasing the bioactivity of nutrients |
CN113321607A (zh) * | 2020-02-28 | 2021-08-31 | 北京福元医药股份有限公司沧州分公司 | 一种阿托伐他汀钙中间体的纯化方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003960A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) |
WO2000071116A1 (en) * | 1999-05-25 | 2000-11-30 | Ranbaxy Laboratories Limited | Process for the production of amorphous atorvastatin calcium |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
-
2001
- 2001-01-23 SI SI200100010A patent/SI20814A/sl not_active IP Right Cessation
-
2002
- 2002-01-22 RU RU2003124962/04A patent/RU2324679C2/ru not_active IP Right Cessation
- 2002-01-22 AU AU2002219455A patent/AU2002219455B2/en not_active Ceased
- 2002-01-22 CZ CZ20031988A patent/CZ20031988A3/cs unknown
- 2002-01-22 SI SI200230156T patent/SI1373202T1/sl unknown
- 2002-01-22 SK SK908-2003A patent/SK286593B6/sk not_active IP Right Cessation
- 2002-01-22 HU HU0302797A patent/HU227535B1/hu not_active IP Right Cessation
- 2002-01-22 PL PL361763A patent/PL209428B1/pl unknown
- 2002-01-22 AT AT02734878T patent/ATE294159T1/de active
- 2002-01-22 UA UA2003076436A patent/UA73829C2/uk unknown
- 2002-01-22 BR BR0206637-8A patent/BR0206637A/pt not_active IP Right Cessation
- 2002-01-22 MX MXPA03006548A patent/MXPA03006548A/es active IP Right Grant
- 2002-01-22 CA CA002435954A patent/CA2435954C/en not_active Expired - Fee Related
- 2002-01-22 JP JP2002559389A patent/JP4336106B2/ja not_active Expired - Fee Related
- 2002-01-22 EE EEP200300333A patent/EE05270B1/xx not_active IP Right Cessation
- 2002-01-22 EP EP02734878A patent/EP1373202B1/en not_active Expired - Lifetime
- 2002-01-22 RS YUP-568/03A patent/RS51010B/sr unknown
- 2002-01-22 WO PCT/IB2002/000161 patent/WO2002059087A1/en active IP Right Grant
- 2002-01-22 IL IL15706802A patent/IL157068A0/xx unknown
- 2002-01-22 CN CNB028039688A patent/CN1260213C/zh not_active Expired - Fee Related
- 2002-01-22 ES ES02734878T patent/ES2240748T3/es not_active Expired - Lifetime
- 2002-01-22 DE DE60203894T patent/DE60203894T2/de not_active Expired - Lifetime
- 2002-01-22 KR KR1020037009509A patent/KR100882066B1/ko not_active IP Right Cessation
- 2002-01-22 DK DK02734878T patent/DK1373202T3/da active
- 2002-12-18 US US10/323,444 patent/US6750353B2/en not_active Expired - Fee Related
-
2003
- 2003-07-09 ZA ZA200305307A patent/ZA200305307B/xx unknown
- 2003-07-15 HR HR20030575A patent/HRP20030575B1/xx not_active IP Right Cessation
- 2003-07-22 BG BG108017A patent/BG108017A/bg unknown
- 2003-07-23 IL IL157068A patent/IL157068A/en not_active IP Right Cessation
- 2003-10-03 US US10/677,344 patent/US7074940B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003960A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) |
WO2000071116A1 (en) * | 1999-05-25 | 2000-11-30 | Ranbaxy Laboratories Limited | Process for the production of amorphous atorvastatin calcium |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030575B1 (en) | Preparation of non-crystalline atorvastatin calcium | |
ATE477238T1 (de) | Verfahren zur herstellung von dithioestern | |
JP2005503997A5 (ko) | ||
BRPI0413728B8 (pt) | muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína | |
BR0113494A (pt) | Processo para a preparação de uma formulação sólida herbicida, e, uso de uma formulação sólida herbicida | |
BRPI0402986A (pt) | Processo para a preparação de subóxido de nióbio | |
SI21463B (sl) | Postopek za pripravo heksahidro-furo/2,3-b/furan-3-ola | |
DE60117963D1 (de) | Verfahren zu herstellung von citalopram | |
ES2143443T3 (es) | Espesantes polimeros para composiciones acuosas. | |
RU2007122353A (ru) | Способ получения гидробромида галантамина | |
AR054340A1 (es) | Composiciones para el tratamiento del cabello | |
ATE345766T1 (de) | Topische zusammensetzungen mit einer äusseren ölphase und verfahren zu deren herstellung | |
ATE295716T1 (de) | Mittel und verfahren zu dauerhaften haarverformung auf basis von 2- mercaptopropionsäureamiden sowie verfahren zu deren herstellung | |
JP2002194078A (ja) | 重合体及びその製造方法 | |
FR2850573B1 (fr) | Utilisation de l'acide 3-0-acetyl 11-ceto-boswellique ou d'un extrait vegetal en contenant, pour reduire les rides d'expression | |
De Rosa et al. | First synthesis of 2-aminopyrrole and simple 1-substituted-2-aminopyrroles. Observation of fast proton exchange at C-5. | |
ITVA20030002A1 (it) | Addensanti sintetici per cosmetici. | |
CA2460970A1 (en) | Processes for preparing crystalline and amorphous mupirocin calcium | |
KR920002510A (ko) | 4-하이드록시부틸 (메트)아크릴레이트의 제조방법 | |
KR920004332A (ko) | 수용액중의 l-포스피노트리신 및 l-글루탐산의 추출분리법 | |
EP0402935A3 (en) | Method of producing n-alkylaminophenols | |
RU98111764A (ru) | Способ получения соли клавулановой кислоты | |
RU2006118318A (ru) | Неводные композиции для нанесения покрытий | |
KR840001121A (ko) | 데카복실라제- 저해제인 플루오르화 알칸디아민유도체의 제조방법 | |
KR960022431A (ko) | 미나리로부터 카페익산을 추출하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20111222 Year of fee payment: 11 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20130123 |